Veri’s data platform's goal is to promote progress in precision oncology by collecting up to date predictive biomarkers of drug response. At EMSO-GI 2020, we presented the advances made in the form of cancer-biomarker-drug associations.
The goal of Veri’s data platform is to promote progress in precision oncology by collecting up to date predictive biomarkers of drug response. It collects expert-curated predictive associations (biomarker-cancer-drug) coming from multiple sources like publications, clinical trials or conferences, among others.
Recently, ESMO’s World Congress on Gastrointestinal Cancer (ESMO-GI) took place virtually bringing together the latest achievements in this field. Here, we present the advances made in the form of cancer-biomarker-drug associations, many of which had not been previously reported.
To discover more about ESMO-GI 2020 advances and ultimately the biomarker-drug associations, visit veri.larvol.com. You can access the full plot.ly chart here at: https://chart-studio.plotly.com/~larvol/1/#/
The advent of precision oncology is marked by many new changes and improvements in diagnostic, prognostic and treatment methods for cancer patients. Researchers looking to bring new drugs to market are now also privy to a vast database of material from previously conducted studies thanks to a push forward in research collaborations and the creation of shared data hubs.
Well-established biomarkers in breast cancer today include BRCA1/BRCA2, estrogen and progesterone receptors as well as p53, which is the most studied biomarker in breast cancer. Let’s look at some of the biomarkers that are emerging in this space.